USPTO serial 79444171
NEWCELX
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- PEISECKI, MARK A
- Law office
- TMEG LAW OFFICE 105
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with NEWCELX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of degenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of neurodegenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of metabolic disorders; pharmaceutical preparations, namely cell therapy for the treatment of diabetes and ALS; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of ALS; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of narcolepsy; stem cells for medical purposes; pharmaceutical compositions containing stem cells; pharmaceutical compositions containing stem cells for the treatment of degenerative diseases; pharmaceutical compositions containing stem cells for the treatment of neurodegenerative and metabolic diseases. | ACTIVE | — |
| 042 | Research and development services in the field of biotechnology; research and development services in the field of pharmaceutical preparations; research and development services in the field of stem cells; research and development services in the field of cell therapy; research and development of induced pluripotent stem cells; research and development services in the field of pharmaceutical preparations, namely research and development of proprietary cell lines for the treatment of diabetes and ALS; research and development services in the field of pharmaceutical preparations, namely research and development of pluripotent stem cells for the treatment of neurodegenerative and metabolic diseases; scientific research in the medical and pharmaceutical field, and consultancy and information relating thereto; design and development of technology for cell therapy for the treatment of degenerative diseases; pharmaceutical drug development services; development of products for others in the field of pharmaceuticals; scientific services relating to processing human cells; medical and scientific research and development of human stem cells; scientific and technological services in the field of regenerative medicine; scientific and technological services and research and development relating thereto in the field of stem cell-based regenerative therapies for the treatment of neurodegeneration and metabolic disorders; medical and scientific research and development in the field of regenerative medicine; pharmaceutical research and development services in the field of cell regeneration and engineering. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 18, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 2, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 2, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 21, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 20, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 10, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 23, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 23, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 19, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |